Mirum Pharmaceuticals (NASDAQ:MIRM) Receives New Coverage from Analysts at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a report released on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $48.00 target price on the stock.

Several other research analysts have also recently weighed in on MIRM. HC Wainwright restated a buy rating and issued a $58.00 price target on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 2nd. Cantor Fitzgerald restated an overweight rating and issued a $35.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, February 29th. Raymond James decreased their price target on Mirum Pharmaceuticals from $78.00 to $64.00 and set a strong-buy rating for the company in a research note on Tuesday, December 19th. SVB Leerink decreased their price target on Mirum Pharmaceuticals from $44.00 to $43.00 and set an outperform rating for the company in a research note on Monday, March 18th. Finally, JMP Securities lifted their price objective on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an outperform rating in a report on Thursday, March 14th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of Buy and a consensus price target of $51.70.

Mirum Pharmaceuticals Trading Down 0.7 %

MIRM opened at $23.85 on Wednesday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 4.19 and a current ratio of 4.45. The business has a 50 day moving average of $27.04 and a 200-day moving average of $28.56. Mirum Pharmaceuticals has a 52 week low of $23.76 and a 52 week high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 28th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). The firm had revenue of $69.55 million during the quarter, compared to analysts’ expectations of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. As a group, research analysts predict that Mirum Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Insider Activity

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt acquired 2,000 shares of the stock in a transaction dated Monday, March 18th. The shares were acquired at an average cost of $25.80 per share, for a total transaction of $51,600.00. Following the completion of the transaction, the chief financial officer now directly owns 12,000 shares of the company’s stock, valued at $309,600. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt acquired 2,000 shares of the stock in a transaction dated Monday, March 18th. The shares were acquired at an average cost of $25.80 per share, for a total transaction of $51,600.00. Following the completion of the transaction, the chief financial officer now directly owns 12,000 shares of the company’s stock, valued at $309,600. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Peter Radovich sold 4,303 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $25.80, for a total value of $111,017.40. Following the completion of the sale, the chief operating officer now owns 29,013 shares in the company, valued at $748,535.40. The disclosure for this sale can be found here. Company insiders own 24.06% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently made changes to their positions in MIRM. China Universal Asset Management Co. Ltd. lifted its position in shares of Mirum Pharmaceuticals by 98.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock worth $31,000 after buying an additional 488 shares in the last quarter. AJOVista LLC bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $40,000. Wetzel Investment Advisors Inc. bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $41,000. Royal Bank of Canada grew its stake in shares of Mirum Pharmaceuticals by 40.1% during the second quarter. Royal Bank of Canada now owns 1,851 shares of the company’s stock valued at $48,000 after buying an additional 530 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Mirum Pharmaceuticals by 186.6% during the second quarter. Tower Research Capital LLC TRC now owns 1,846 shares of the company’s stock valued at $48,000 after buying an additional 1,202 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.